Incidence, treatment, and outcomes of atrial fibrillation complicating non-ST-segment elevation acute coronary syndromes.
暂无分享,去创建一个
D. Atar | M. Keltai | R. Giugliano | E. Braunwald | L. Newby | P. Armstrong | H. White | E. Ohman | C. Bode | R. Lopes | N. Kleiman | P. Tricoci | P. Widimsky | U. Zeymer | Jennifer A. White | R. Lopes
[1] Giuseppe Ambrosio,et al. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. , 2012, The New England journal of medicine.
[2] Paul Burton,et al. Rivaroxaban in patients with a recent acute coronary syndrome. , 2012, The New England journal of medicine.
[3] R. Mehta,et al. Naproxen as prophylaxis against atrial fibrillation after cardiac surgery: the NAFARM randomized trial. , 2011, The American journal of medicine.
[4] J. Lessick,et al. Transient atrial fibrillation and risk of stroke after acute myocardial infarction , 2011, Thrombosis and Haemostasis.
[5] Deepak L. Bhatt,et al. Apixaban with antiplatelet therapy after acute coronary syndrome. , 2011, The New England journal of medicine.
[6] X. Jouven,et al. Atrial Fibrillation and Death After Myocardial Infarction: A Community Study , 2011, Circulation.
[7] Hani Jneid,et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in c , 2011, Journal of the American College of Cardiology.
[8] X. Jouven,et al. Mortality Associated With Atrial Fibrillation in Patients With Myocardial Infarction: A Systematic Review and Meta-Analysis , 2011, Circulation.
[9] Silvia G Priori,et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2011, Circulation.
[10] Kenneth A Ellenbogen,et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, Circulation.
[11] Fredrik Folke,et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. , 2010, Archives of internal medicine.
[12] L. Newby,et al. Warfarin use and outcomes in patients with atrial fibrillation complicating acute coronary syndromes. , 2010, The American journal of medicine.
[13] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[14] L. Køber,et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data , 2009, The Lancet.
[15] R. Califf,et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. , 2009, The New England journal of medicine.
[16] P. Sanders,et al. Prognostic impact of types of atrial fibrillation in acute coronary syndromes. , 2009, The American journal of cardiology.
[17] R. Califf,et al. Patterns of management of atrial fibrillation complicating coronary artery bypass grafting: Results from the PRoject of Ex-vivo Vein graft ENgineering via Transfection IV (PREVENT-IV) Trial. , 2009, American heart journal.
[18] Claes Held,et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.
[19] P. Armstrong,et al. Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. , 2009, European heart journal.
[20] L. Newby,et al. Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation , 2008, Heart.
[21] E. Antman,et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.
[22] C. Lau,et al. Transient atrial fibrillation complicating acute inferior myocardial infarction: implications for future risk of ischemic stroke. , 2007, Chest.
[23] I. Porto,et al. Adjusted indirect meta-analysis of aspirin plus warfarin at international normalized ratios 2 to 3 versus aspirin plus clopidogrel after acute coronary syndromes. , 2007, The American journal of cardiology.
[24] J. Hartikainen,et al. Corticosteroids for the prevention of atrial fibrillation after cardiac surgery: a randomized controlled trial. , 2007, JAMA.
[25] Ajai Kumar Jain,et al. PexeLizumab for Acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial , 2007 .
[26] A. Keech,et al. Interventions for prevention of post-operative atrial fibrillation and its complications after cardiac surgery: a meta-analysis. , 2006, European heart journal.
[27] V. Pasceri,et al. Randomized Trial of Atorvastatin for Reduction of Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of MYocardial Dysrhythmia After cardiac surgery) Study , 2006, Circulation.
[28] G. Lip,et al. Is atrial fibrillation an inflammatory disorder? , 2006, European heart journal.
[29] J. Cook,et al. Warfarin plus Aspirin after Myocardial Infarction or the Acute Coronary Syndrome: Meta-Analysis with Estimates of Risk and Benefit , 2005, Annals of Internal Medicine.
[30] S. Yusuf,et al. Clinical ResearchHeart Rhythm DisorderPrevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis , 2005 .
[31] R. Califf,et al. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndro , 2005, American heart journal.
[32] K. Eagle,et al. Comparison of outcomes of patients with acute coronary syndromes with and without atrial fibrillation. , 2003, The American journal of cardiology.
[33] Á. Avezum,et al. Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.
[34] L. Hadjinikolaou,et al. Incidence and Clinical Consequences of Atrial Fibrillation Within 1 Year of First-Time Isolated Coronary Bypass Surgery , 2003, Circulation.
[35] R. Califf,et al. Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience , 2002 .
[36] S. Yusuf,et al. Interventions on Prevention of Postoperative Atrial Fibrillation in Patients Undergoing Heart Surgery: A Meta-Analysis , 2002, Circulation.
[37] W. Stevenson,et al. Atrial Fibrillation after Cardiac Surgery , 2001, Annals of Internal Medicine.
[38] S. Yusuf,et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. , 2001, The New England journal of medicine.
[39] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[40] R. Beyth,et al. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. , 1998, The American journal of medicine.
[41] V. Boyko,et al. Significance of Paroxysmal Atrial Fibrillation Complicating Acute Myocardial Infarction in the Thrombolytic Era , 1998 .
[42] G. W. Snedecor. STATISTICAL METHODS , 1967 .